What records are connected here?
- Evidence lanes
- 3
- Source years
- 12
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Smaller human trialsGut and digestion
Teduglutide is a lab-made analogue of glucagon-like peptide-2 (GLP-2), a gut hormone that supports the lining of the intestine, and is the active ingredient in Gattex.1,2 FDA approved Gattex in 2012 for short bowel syndrome in people who depend on parenteral support, nutrition or fluids given through a vein. It is approved for adults and for children 1 year and older.1,2 In a randomized, placebo-controlled trial of 86 adults, 63% on teduglutide cut their weekly parenteral support by at least a fifth, versus 30% on placebo. The label warns that it may speed the growth of existing tumors.1
| What it is | An analogue of human GLP-2 that binds GLP-2 receptors in the intestine, according to the label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Gattex with an original approval date of December 21, 2012. The cited label has no boxed warning.1,2 |
| Human evidence | A randomized, double-blind, placebo-controlled trial in 86 adults with short bowel syndrome and its two-year open-label extension, described in the label.1 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Teduglutide is a synthetic analogue of glucagon-like peptide-2 (GLP-2), a peptide released by cells of the lower intestine.1
In the United States it is the active ingredient of Gattex, from Takeda, according to Drugs@FDA.2
The label states that GLP-2 increases blood flow to the intestine and reduces stomach acid, and that teduglutide binds GLP-2 receptors on cells and nerves in the intestinal wall.1
The label states that activating these receptors releases several local signalling molecules in the intestinal wall.1
In Study 1, 86 adults with short bowel syndrome were randomized to teduglutide or placebo. At weeks 20 and 24, 63% (27 of 43) on teduglutide and 30% (13 of 43) on placebo had at least a 20% reduction in weekly parenteral support, according to the label.1
In the open-label extension, 28 of 30 patients who completed 30 months of treatment had at least a 20% reduction, and 10 no longer needed parenteral support, according to the label.1
The label also describes a second placebo-controlled trial in adults (Study 3) and two studies in which 41 children aged 1 to under 17 received it.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Yes. Drugs@FDA lists Gattex, application NDA 203441, with an original approval date of December 21, 2012.2
The Gattex label cited here (DailyMed SPL version 20, published September 18, 2025) states that it is indicated for adults and children 1 year and older with short bowel syndrome who are dependent on parenteral support.1
The label has no boxed warning. Its warnings include possible acceleration of tumor growth, with colon screening recommended, intestinal obstruction, gallbladder, bile duct and pancreas disease, and fluid overload.1
Its long-term tumor risk, which the label addresses with a warning and recommended screening rather than settled data.1
Which patients will be able to stop parenteral support entirely: in the extension, 10 of 30 long-term patients did.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Teduglutide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Teduglutide are a bounded selection, not every registration or paper about Teduglutide. For the years before Teduglutide was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Teduglutide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Teduglutide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Gattex for short bowel syndrome. A randomized, placebo-controlled trial of 86 adults described in the label found that more patients reduced parenteral support with teduglutide. The label warns of possible acceleration of tumor growth.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Gattex for short bowel syndrome. A randomized, placebo-controlled trial of 86 adults described in the label found that more patients reduced parenteral support with teduglutide. The label warns of possible acceleration of tumor growth.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date September 8, 2026
ClinicalTrials.gov record NCT06973304↗Added to PeptideScanner November 15, 2026Clinical trials · added November 15, 2026
ClinicalTrials.gov record NCT06973304↗Source date September 8, 2026Literature metadata · added November 15, 2026
Real-life experience of teduglutide use in pediatric patients with short bowel syndrome in Argentina. A multicenter study.↗Source date February 8, 2026Literature metadata · added November 15, 2026
Teduglutide in pediatric intestinal failure: A position statement of the Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP).↗Source date January 27, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
30 of 30 selected trial records include at least one phase value; 30 of 30 include a status value in the retained structured contract.
24 of 24 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00072839 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-05-25, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00081458 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00172185 at 2026-11-15T21:55:23.600Z. Its registry update date was 2021-06-02, and PeptideScanner's reviewed identity mapping was teduglutide.
24 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span May 7, 2012 to September 8, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06973304 at 2026-11-15T21:55:23.600Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was teduglutide.↗
Literature metadata
PubMed lists PMID 41647102 in Intestinal Failure (New York, N.Y.) as Journal Article, with publication-date metadata of 2024-11-28 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 35654733 in Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver as Journal Article, Review, Consensus Statement, with publication-date metadata of 2022-05-31 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 36177820 in Revista espanola de enfermedades digestivas as Case Reports, Journal Article, with publication-date metadata of 2023-06 (month precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 37001195 in Clinical nutrition (Edinburgh, Scotland) as Journal Article, with publication-date metadata of 2023-03-18 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 37270288 in The American journal of clinical nutrition as Journal Article, with publication-date metadata of 2023-05-03 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 40764045 in BMJ open gastroenterology as Journal Article, with publication-date metadata of 2025-08-05 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03562130 at 2026-11-15T21:55:23.600Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was teduglutide.↗
Literature metadata
PubMed lists PMID 40771220 in Frontiers in nutrition as Case Reports, Journal Article, with publication-date metadata of 2025-07-23 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 40086997 in Endocrinologia, diabetes y nutricion as Case Reports, Journal Article, Review, with publication-date metadata of 2025-03 (month precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02949362 at 2026-11-15T21:55:23.600Z. Its registry update date was 2025-03-19, and PeptideScanner's reviewed identity mapping was teduglutide.↗
Literature metadata
PubMed lists PMID 39125394 in Nutrients as Journal Article, Multicenter Study, Observational Study, with publication-date metadata of 2024-08-01 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026